Abstract

Piper nigrum is well known for antioxidant activity. Neurodegenerative disorders including Parkinsonism involve oxidative stress as major cause. Existing study was conducted to explore effect of ethanolic extract of P. nigrum (PN) fruits on orofacial dyskinesia induced by reserpine in Wistar rats. Body weight, behavioural and biochemical parameters were evaluated. PN significantly reversed parameters of reserpine induced orofacial dyskinesia including vacuous chewing movements, tongue protrusions and orofacial bursts. PN reversed cognitive impairment induced by reserpine assessed using elevated plus maze and locomotion assessed using open field apparatus. PN also reversed levels of anti-oxidant enzymesviz superoxide dismutase, catalase, glutathione reductase and extent of lipid peroxidation and exhibited protective effect against oxidative damage induced by reserpine.

Keywords: Neurodegeneration, Oxidative Stress, Piper nigrum, Reserpine

References

1. Cadet JL and Lohr JB. “Possible involvement of free radicals in neuroleptic‐induced movement disorders evidence from treatment of tardive dyskinesia with Vitamin E, Annals New York”. Academy of Sciences 1 (1989): 176-185.
2. Naidu PS., et al. “Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia”. Neuropharmacology 44 (2003): 1100-1106.
3. Burger ME., et al. “Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain”. Pharmacology Biochemistry and Behavior 3 (2005): 608-615.
4. Alirezalu K., et al. “Combined effect of natural antioxidants and antimicrobial compounds during refrigerated storage of nitrite-free frankfurter-type sausage”. Food Research International 120 (2019): 839-850.
5. Pateiro M., et al. “Plant extracts obtained with green solvents as natural antioxidants in fresh meat products”. Antioxidants2 (2021): 181.
6. Wei X., et al. “Radiofrequency pasteurization process for inactivation of Salmonella spp. and Enterococcus faecium NRRL B-2354 on ground black pepper”. Food Microbiology 82 (2019): 388-397.
7. Wang Y., et al. “Comparative Analysis of Intracellular and in vitro Antioxidant Activities of Essential Oil From White and Black Pepper (Piper nigrum L.)”. Frontiers in Pharmacology 12 (2021): 1344.
8. Trease and Evans Pharmacognosy - William Charles Evans (edition.), 16th Edition, WB Saunders, Edinburgh, UK (2019).
9. Neisweinder JL., et al. “Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia”. The Journal of Psychopharmacology 16 (1994): 79-84.
10. Patil RA and Salade PD. “Protective effect of proanthocynidins from M. nagi bark (PMN) on reserpine-induced orofacial dyskinesia in experimental animals”. Journal of Advanced Scientific Research 1 (2021): 195-203.
11. Vogel HG. “Drug discovery and evaluation: pharmacological assays”. Springer Science and Business Media (2002).
12. Patil RA and Salade PD. “Proanthocyanidin rich fraction of M. nagi bark (PMN) attenuates reserpine-induced impairment of cognition and locomotion in experimental animals”. European Journal of Molecular and Clinical Medicine 06 (2020): 4923-4929.
13. Jaiswal AK. “Antioxidant response element”. Biochemical Pharmacology 3 (1994): 439-444.
14. Saggu H., et al. “Selective increase in particulate Superoxide dismutase activity in Parkinsonian substansia nigra”. Journal of Neurochemistry 53 (1989): 692-697.
15. Misra HP and Fridovich I. “The generation of superoxide radical during the auto-oxidation of haemoglobin”. Journal of Biological Chemistry 247 (1983): 6960-6962.
16. Beers RFJr and Sizer IW. “A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase”. Journal of Biological Chemistry (1952): 133-140.
17. Ellman GL. “Tissue sulfhydryl groups”. Archives of Biochemistry and Biophysics 82 (1959): 70-77.
18. Niehaus Jr WG and Samuelsson B. “Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation”. European Journal of Biochemistry 1 (1968): 126-130.
19. Mahadik SP and Scheffer RE. “Oxidative injury and potential use of antioxidants in schizophrenia”. Prostaglandins, Leukotrienes and Essential Fatty Acids 1-2 (1996): 45-54.
20. Balijepalli S., et al. “Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics”. Neurochemistry International 5 (2001): 425-435.
21. Cadet JL., et al. “Free radicals and tardive dyskinesia”. Trends in Neurosciences 9 (1986): 107-108.
22. Andreassen OA and Jørgensen HA. “Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: implications for tardive dyskinesia?” Progress in Neurobiology 5 (2000): 525-541.
23. Patil RA and Kasture SB. “Protective effect of Rubia cordifolia on reserpine-induced orofacial dyskinesia”. Natural Product Research 22 (2012): 2159-2161.
24. Patil R., et al. “Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals”. Pharmaceutical Biology 6 (2012): 691-697.
25. Dusica P and Vesna T. “Oxidative stress as marker of positive symptoms in schizophrenia”. Medical Biology 2 (2002): 157-161.
26. Cadet JL and Lohr JB. “Free radicals Mechanism in schizophrenia and tardive dyskinesia”. Neuroscience and Biobehavioral Reviews 4 (1994): 457-467.
27. Reddy RD and Yao JK. “Free radical pathology in schizophrenia: a review”. Prostaglandins, Leukotrienes and Essential Fatty Acids 1-2 (1996): 33-43.
28. Lohr JB., et al. “Oxidative mechanisms and tardive dyskinesia”. CNS Drugs 1 (2003): 47-62.
29. Schonecker M. “A strange syndrome in the oral area with application of chlorpromazine”. Nervenarzt 28 (1957): 35.
30. Uhrbrand L and Faurbye A. “Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy”. Psychopharmacologia 1 (1960): 408-418.
31. Kroeze WK., et al. “H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs”. Neuropsychopharmacology3 (2003): 519-526.
32. Stanton JM. “Weight gain associated with neuroleptic medication: a review”. Schizophrenia Bulletin 21 (1995): 463-472.
33. Reynolds GP., et al. “Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism”. Lancet 359 (2002): 2086-2087.
34. Carlsson A. “Chemical neurotransmission and mental function: Pharmacological aspects”. In: Hedqvist SL., et al. “Chemical transmission 75 years”. London: Academic Press (1981): 527-540.
35. Salamone JD. “Different effects of haloperidol and extinction on instrumental behaviours”. The Journal of Psychopharmacology 1 (1986): 18-23.
36. Lohr JB. “Oxygen radicals and neuropsychiatric illness: some speculations”. Archives of General Psychiatry 12 (1991): 1097-1106.
37. Kopustinskiene DM., et al. “Flavonoids as Anticancer Agents”. Nutrients2 (2020): 457.